This analysis reveals that baseline white blood cell (WBC) count significantly modifies the impact of anti-pseudomonal antibiotic choice on 28-day mortality in sepsis. Notably, patients with a WBC count ≥16 showed improved survival with piperacillin-tazobactam compared to cefepime. These findings emerged consistently across two large clinical datasets, underscoring the potential of WBC as a biomarker for antibiotic selection and predictive enrichment in future trials.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
